Related Experiment Videos
Interleukin 7 induces CD4+ T cell-dependent tumor rejection
H Hock1, M Dorsch, T Diamantstein
1Institut für Immunologie, Universitätsklinikum Steglitz, Freie Universität Berlin, Federal Republic of Germany.
The Journal of Experimental Medicine
|December 1, 1991
Summary
Interleukin 7 (IL-7) gene transfer into tumors triggers a potent antitumor response in mice. This rejection depends on CD4+ T cells and macrophages, highlighting IL-7
Area of Science:
- Immunology
- Cancer Research
- Molecular Biology
Background:
- Interleukin 7 (IL-7) is a cytokine crucial for lymphocyte development and homeostasis.
- Investigating IL-7's potential for inducing antitumor immunity is essential for novel cancer therapies.
Purpose of the Study:
- To analyze the in vivo potential of interleukin 7 (IL-7) to induce an antitumor response.
- To elucidate the cellular mechanisms underlying IL-7-mediated tumor rejection.
Main Methods:
- Gene transfer of IL-7 into a plasmacytoma cell line (J558L).
- In vivo tumor rejection assays in syngeneic and nude mice.
- Immunohistochemical analysis of tumor-infiltrating lymphocytes and myeloid cells.
- T cell subset depletion studies (CD4+ and CD8+).
- Inhibition studies using anti-IL-7 monoclonal antibody.
Main Results:
- IL-7-producing tumor cells were completely rejected in syngeneic mice but not in nude mice.
- Tumor rejection was dependent on IL-7 and abolished by anti-IL-7 antibody.
- IL-7 induced infiltration of CD4+ T cells, CD8+ T cells, and CR3+ cells (macrophages) into tumors.
- Antitumor response critically depended on CD4+ T cells and CR3+ cells, but not CD8+ T cells.
Conclusions:
- High local IL-7 concentration via gene transfer effectively mediates tumor rejection.
- The mechanism involves CD4+ T cells and macrophages, distinct from other cytokine-based therapies.
- Targeted IL-7 gene delivery shows promise for cancer immunotherapy.